Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Sep;15(3):165–171. doi: 10.1007/BF00199159

Serial immune function testing to predict clinical disease relapse in patients with solid tumors

Donald P Braun 1,✉, Jules E Harris 1
PMCID: PMC11039147  PMID: 6352007

The content is available as a PDF (979.5 KB).

References

  • 1.Anthony HM, Kirk JA, Madsen KE, Mason MK, Templeman GH. E and EAC rosetting lymphocytes in patients with carcinoma of bronchus. II. A sequential study of thirty patients: Effect of BCG. Clin Exp Immunol. 1975;20:41. [PMC free article] [PubMed] [Google Scholar]
  • 2.Berkelhammer J, Mastrangelo MJ, Bellet RE, Prehn RT, Thibaults LH. Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy. Eur J Cancer. 1978;14:793. doi: 10.1016/0014-2964(78)90011-7. [DOI] [PubMed] [Google Scholar]
  • 3.Berkelhammer J, Mastrangelo MJ, Bellet RE, Berd D, Prehn RT. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients. Eur J Cancer. 1979;15:197. doi: 10.1016/0014-2964(79)90060-4. [DOI] [PubMed] [Google Scholar]
  • 4.Bolton PM, Mander AM, Davidson JM, James SL, Newcombe RG, Hughes LE. Cellular immunity in cancer: Comparison of delayed hypersensitivity skin tests in three common cancers. Br Med J. 1975;III:18. doi: 10.1136/bmj.3.5974.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Braun DP, Harris JE. Effects of combination chemotherapy on immunoregulatory cells in the peripheral blood of solid tumor cancer patients: Correlation with rebound overshoot immune function recovery. Clin Immunol Immunopathol. 1981;20:193. doi: 10.1016/0090-1229(81)90178-1. [DOI] [PubMed] [Google Scholar]
  • 6.Braun DP, Nisius S, Hollinshead A, Harris JE (1983) Serial immune testing in surgically resected lung cancer patients. Cancer Immunol Immunopathol (in press) [DOI] [PMC free article] [PubMed]
  • 7.Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, Skaggs C. Immunobiology of primary intracranial tumors. V. Correlation of lymphocyte index and clinical status. J Neurosurg. 1979;54:331. doi: 10.3171/jns.1981.54.3.0331. [DOI] [PubMed] [Google Scholar]
  • 8.Brosman S, Elhilali M, Vescera C, Fahey J. Immune response in bladder cancer patients. J Urol. 1979;121:162. doi: 10.1016/s0022-5347(17)56707-5. [DOI] [PubMed] [Google Scholar]
  • 9.Catalona WJ, Ratliff TL, McCool RS. Concanavalin A-activated suppressor cells in peripheral blood and lymph nodes of urologic cancer patients. Surg Forum. 1979;6:21. [PubMed] [Google Scholar]
  • 10.Cunningham TJ, Daut D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, Horton J. A correlation of DNCB-induced delayed cutaneous hypersensitivity reactions and the course of disease in patients with recurrent breast cancer. Cancer. 1976;37:1686. doi: 10.1002/1097-0142(197604)37:4<1696::aid-cncr2820370413>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  • 11.Cummingham MP, Caprini JA, Oviedo MA, Cohen E, Robinson B, Scanlon EF. Immune responses and recurrences in Stage II and III breast cancer patients undergoing adjuvant chemoimmunotherapy. In: Crispen RG, editor. Tumor progression. Amsterdam: Elsevier North/Holland; 1980. p. 355. [Google Scholar]
  • 12.Dean JH, Cannon GB, Jerrels TR, McCoy JL, Herberman RB. Sensitive measurement of immunocompetence and antitumor reactivity in lung cancer patients and possible mechanisms of immunosuppression. In: Crispen RG, editor. Neoplasm immunity: Experimental and clinical. Amsterdam: Elsevier/North Holland; 1980. p. 357. [Google Scholar]
  • 13.Dellon AC, Potvin C, Chretieu PB. Thumus-dependent lymphocyte levels in bronchogenic carcinoma: Correlations with histology, clinical stage and clinical course after surgical treatment. Cancer. 1975;35:687. doi: 10.1002/1097-0142(197503)35:3<687::aid-cncr2820350322>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 14.Eilber FR, Nizze JA, Morton DL. Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course. Cancer. 1975;35:660. doi: 10.1002/1097-0142(197503)35:3<660::aid-cncr2820350319>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 15.Engleman EG, Benike CJ, Hoppe RT, Kaplan HS, Berberich FR. Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. J Clin Invest. 1980;66:149. doi: 10.1172/JCI109828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Evans CM, Bowen JG. Immunological tests in carcinoma of the prostate. Proc R Soc Med. 1977;70:417. [PMC free article] [PubMed] [Google Scholar]
  • 17.Glass U, Wasserman J, Blomgren H, de Schryver A. Lymphopenia and metastatic breast cancer patients with and without radiation therapy. Int J Rad Oncol Biol Phys. 1976;1:189. doi: 10.1016/0360-3016(76)90040-7. [DOI] [PubMed] [Google Scholar]
  • 18.Golub SH, Forsythe AB, Morton DL. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy. Int J Cancer. 1977;19:18. doi: 10.1002/ijc.2910190104. [DOI] [PubMed] [Google Scholar]
  • 19.Gross NJ, Eddie-Quartery AC. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease. Cancer. 1976;37:2183–2193. doi: 10.1002/1097-0142(197605)37:5<2183::aid-cncr2820370505>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  • 20.Gross RL (1978) Current status of immunologic studies in human lung cancer. Los Alamos Scientific Laboratory; U.S. Department of Commerce, National Technical Information Service (June)
  • 21.Hakala TR, Lange PH, Elliott AY, Fraley EE. Changes in cell-mediated cytotoxicity during the clinical course of patients with bladder carcinoma. J Urol. 1976;115:268. doi: 10.1016/s0022-5347(17)59168-5. [DOI] [PubMed] [Google Scholar]
  • 22.Harris JE, DeBoer KP, Vahey AL, Braun DP. The measurement of leukocyte subsets in the peripheral blood of solid tumor cancer patients using monoclonal antibody reagents. Med Pediatr Oncol. 1982;10:185. doi: 10.1002/mpo.2950100214. [DOI] [PubMed] [Google Scholar]
  • 23.Haynes BF, Katz P, Fauci AS. Immune responses of human lymphocytes in vitro. Prog Clin. 1980;4:23. [PubMed] [Google Scholar]
  • 24.Hedley DW, Nyholm RE, Currie GA. Monocytes and macrophages in malignant melanoma. IV. Effects of C. parvum on monocyte function. Br J Cancer. 1979;39:558. doi: 10.1038/bjc.1979.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hellstrom I, Warner GA, Hellstrom KE, Sjogren HO. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer. 1973;11:280. doi: 10.1002/ijc.2910110206. [DOI] [PubMed] [Google Scholar]
  • 26.Herberman RB. In vitro tests of cellular immunity in man. Invest Cell Pathol. 1978;1:227. [PubMed] [Google Scholar]
  • 27.Herberman RW. Assessment of cellular immune response to cancer of the breast. Ann Clin Lab Sci. 1979;9:467. [PubMed] [Google Scholar]
  • 28.Jones BM, Turnbull AR. Horizontal studies of cell-mediated immune reactions to autologous tumour antigens in patients with operable mammary carcinoma. Br J Cancer. 1975;32:33. doi: 10.1038/bjc.1975.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Karavodin LM, Giuliano AE, Golub SH. T lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother. 1981;11:251. [Google Scholar]
  • 30.Kerman RH, Stefani SS. Effect of BCG immunotherapy on the active-T and total T-RFC in patients with lung cancer. Cancer Immunol Immunother. 1978;4:41. [Google Scholar]
  • 31.Kerman RH, Smith R, Stafani SS, et al. Active T rosette forming cells in the peripheral blood of cancer patients. Cancer Rev. 1976;36:3274. [PubMed] [Google Scholar]
  • 32.Kristensen E, Reimann R. Direct cytotoxicity test applied to patients in Stage I and Ii of malignant skin melanoma. I. Specificity and prognostic value. Cancer Immunol Immunother. 1977;2:49. [Google Scholar]
  • 33.Lamelin J-P, Ellouz R, deThe G, Revillard JP. Lymphocyte subpopulations and mitogenic responses in nasopharyngeal carcinoma, prior to and after radiotherapy. Int J Cancer. 1977;20:723. doi: 10.1002/ijc.2910200512. [DOI] [PubMed] [Google Scholar]
  • 34.Levin AS, Byers VS, Fudenberg HH, Wybran J, Hackett AJ, Johnston JD, Spitler LE. Immunological parameters before and during immunotherapy with tumor-specific transfer factor. J Clin Invest. 1975;55:487–499. doi: 10.1172/JCI107955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lopez M, O'Connor R, Macfarlane JK, Thomson DMP. The natural history of antitumour immunity in human breast cancer assayed by tube leucocyte adherence inhibition. Br J Cancer. 1978;38:660. doi: 10.1038/bjc.1978.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Martinez-Pineiro JA, Muntanola P, Hidalgo L. Immunological evaluatio of patients with urological cancers. Eur Urol. 1977;3:159. doi: 10.1159/000472083. [DOI] [PubMed] [Google Scholar]
  • 37.McCoy JL, Jerome LF, Cannon GB, Weese JL, Herberman RB. Reactivity of lung cancer patients in leukocyte migration inhibition assays to 3-M potassium chloride extracts of fresh tumor and tissue-cultured cells derived from lung cancer. J Natl Cancer Inst. 1977;59:1413. doi: 10.1093/jnci/59.5.1413. [DOI] [PubMed] [Google Scholar]
  • 38.McMahon LJ, Thomson SP, Nugent CA, Denny WF, Miller TP. Persistent lymphocytopenia as a diagnostic feature of bronchogenic carcinoma. Chest. 1980;78:583. doi: 10.1378/chest.78.4.583. [DOI] [PubMed] [Google Scholar]
  • 39.Neilan BA. Lack of correlation of T and B lymphocytes with stage of colorectal carcinoma. Dis Colon Rectum. 1980;23:65. doi: 10.1007/BF02587593. [DOI] [PubMed] [Google Scholar]
  • 40.Ninger E, Zemarova D, Kovarik J, Lauerova L. Evaluation of three E-rosette assays in melanoma patients. Cancer Immunol Immunother. 1979;6:121. [Google Scholar]
  • 41.Nishio S, Horii A, Morikawa Y, Kawakita J, Nishijima T, Kishimoto T, Maekawa M. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. Invest Urol. 1979;16:336. [PubMed] [Google Scholar]
  • 42.Oldham D, Weese JL, Herberman RB, Perlin E, et al. Immunological monitoring and immunotherapy of carcinoma of the lung. Int J Cancer. 1976;18:739. doi: 10.1002/ijc.2910180604. [DOI] [PubMed] [Google Scholar]
  • 43.Oldham RK, Gail MH, Baker MA, Forbes JT, Heineman W, Hersh E, Carmack Holmes E, Ritts RE, Wright PW. Immunological studies in double blind randomized trial comparing intrapleural BCG against placebo in patients with resected Stage I nonsmall cell lung cancer. Cancer Immunol Immunother. 1982;13:154–173. doi: 10.1007/BF00205382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.O'Toole C. A 51chromium isotopoe release assay for detecting cytotoxicity to human bladder carcinoma. Int J Cancer. 1977;19:324. doi: 10.1002/ijc.2910190307. [DOI] [PubMed] [Google Scholar]
  • 45.Payne JE, Meyer JH, Macpherson JG, Nelson DS, Walls RS, Pheils MT. The value of lymphocyte transformation in carcinoma of the colon and rectum. Surg Gynecol Obstet. 1980;150:687. [PubMed] [Google Scholar]
  • 46.Rieche K, Arndt A, Pasternak G. Cellular immunity in mammary cancer patients as measured by the leukocyte migration test (LMT). A follow-up study. Int J Cancer. 1976;17:212. doi: 10.1002/ijc.2910170210. [DOI] [PubMed] [Google Scholar]
  • 47.Saal JG, Riethmuller LG, Rieber EP, Hadam M, Ehinger H, Schneider W. Regional BCG-therapy of malignant melanoma: In vitro monitoring of spontaneous cytolytic activity of circulating lymphocytes. Cancer Immunol Immunother. 1977;3:27. [Google Scholar]
  • 48.Stefani S, Kerman R, Abbate J. Immune evaluation of lung cancer patients undergoing radiation therapy. Cancer. 1976;37:2792. doi: 10.1002/1097-0142(197606)37:6<2792::aid-cncr2820370634>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  • 49.Stewart T, Hollinshead A, Harris JE, et al. Specific active chemoimmunotherapy in lung cancer: A survival study. Recent Results Cancer Res. 1979;68:278. doi: 10.1007/978-3-642-81332-0_43. [DOI] [PubMed] [Google Scholar]
  • 50.Theofilopoulos AN, Dixon FJ. The biology and detection of immune complexes. Adv Immunol. 1979;28:89. doi: 10.1016/s0065-2776(08)60800-7. [DOI] [PubMed] [Google Scholar]
  • 51.Thomas JW, Plenderleith IH, Clements DV, Landi S. Observations in immunotherapy of lymphoma and melanoma patients. Clin Exp Immunol. 1975;21:82. [PMC free article] [PubMed] [Google Scholar]
  • 52.Thyme GS, Moertel CG, Silvers A. Preoperative lymphocyte counts in peripheral blood in patients with colorectal neoplasms: A correlation with tumor type, Duke's classification, site of primary tumor, and five-year survival rate in 1,000 patients. Dis. Colol Rectum. 1979;22:221. doi: 10.1007/BF02586878. [DOI] [PubMed] [Google Scholar]
  • 53.Wanebo HJ. Immunologic testing as a guide to cancer management. Surg Clin North Am. 1979;59:323. doi: 10.1016/s0039-6109(16)41788-3. [DOI] [PubMed] [Google Scholar]
  • 54.Wanebo HJ, Thaler HT, Hansen JA, Rosen PP, Robbins GF, et al. Immunologic reactivity in patients with primary operable breast cancer. Cancer. 1978;41:84. doi: 10.1002/1097-0142(197801)41:1<84::aid-cncr2820410113>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 55.Webster DJT, Richardson G, Baum M, Priestman T, Hughes LE. Effect of treatment on the immunological status of women with advanced breast cancer. Br J Cancer. 1979;39:676. doi: 10.1038/bjc.1979.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Weese JL, Oldham RK, Tormey DC, et al. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet. 1977;145:209. [PubMed] [Google Scholar]
  • 57.Weese JL, West W, Herberman R, et al. Depression of “high affinity” T-cell rosettes indicative of recurrent carcinoma. Surg Forum. 1977;28:15. [PubMed] [Google Scholar]
  • 58.Woosley RE, Mahaley S, Jr, Mahaley JL, Miller GM, Brooks WH. Immunobiology of primary intracranial tumors. Neurosurgery. 1977;47:871. doi: 10.3171/jns.1977.47.6.0871. [DOI] [PubMed] [Google Scholar]
  • 59.Wybran J, Fudenberg HH. Thymus-derived rosette-forming cells in various human disease states: Cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest. 1973;52:1026. doi: 10.1172/JCI107267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Yoshino J. Studies on postoperative changes of nonspecific cell-mediated immunity in patients with gastric cancer. Nippon Gega Gakkai Zasshi. 1981;82:355. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES